Why Aphios’ Bryoid composition patent matters beyond Alzheimer’s disease research
Aphios has a new Bryoid patent allowance. The bigger test is whether marine-derived PKC biology can move from IP promise to clinical proof.
Leqembi’s sales curve just got a new number. BioArctic investors may not ignore it
Leqembi’s Alzheimer’s rollout is still slow, but Eisai’s 2028 sales simulation keeps BioArctic’s royalty story alive.
Why clinical biomarkers face a slow climb before regulators accept them as surrogate endpoints
Biomarkers can speed drug approvals, but weak validation can haunt sponsors. FDA and EMA are tightening the path from signal to endpoint.
Why Fosun Pharma’s AriBio deal could reshape the race for oral Alzheimer’s therapies
Alzheimer’s drugs are moving beyond antibodies. Fosun Pharma’s AR1001 option turns one Phase 3 readout into a global commercial test.
Why Europe’s Alzheimer’s testing pathway could shift after Fujirebio’s latest CE marking
Alzheimer’s testing needs scale, not just science. Fujirebio’s CE-marked pTau 217 assay pushes blood biomarkers closer to routine care.
FDA review extension keeps Eisai and Biogen waiting on Leqembi Iqlik starting-dose strategy
Alzheimer’s drugs need easier delivery. Eisai and Biogen now face an FDA timing test that could shape Leqembi’s access story.
Alpha Cognition expands ALPHA-1062 into traumatic brain injury, but approval is still a distant goal
Alpha Cognition won a U.S. patent for ALPHA-1062 in TBI. Read why the IP matters, what it changes, and where the biggest risks still remain.
Can Lunai Bioworks Inc.’s BBB delivery platform unlock scalable Alzheimer’s drug development advantages?
Can Lunai Bioworks Inc. overcome the blood brain barrier in Alzheimer’s treatment? Discover what this $20M deal changes for CNS drug development.
Why Roche’s Phase III bet on prasinezumab is bigger than its Phase IIb result suggests
Roche and BMS present updated prasinezumab and BMS-986446 data at AD/PD 2026. What it means for Phase III plans and tau targeting. Read the analysis.
C2N Diagnostics advances PrecivityTauDx programme as tangle biomarker gains Phase 3 evidence
C2N’s eMTBR-tau243 plasma assay shows independent prognostic value in Phase 3 Evoke data. What this means for Alzheimer’s patient selection. Read the analysis.